Mammary analogue secretory carcinoma: Update on a new diagnosis of salivary gland malignancy

Authors


  • Funding: This work was supported by a grant from the Doris Duke Charitable Foundation to Harvard Medical School to fund Clinical Research Fellow Roshan Sethi. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objectives/Hypothesis

To review the known histopathologic findings and clinical behavior of mammary analogue secretory carcinoma (MASC).

Data Sources

PubMed.

Review Methods

Literature search using the terms “Mammary analogue secretory carcinoma,” “Mammary analog secretory carcinoma,” and “MASC” to identify all relevant publications.

Results

MASC is an unusual and rare malignant salivary gland tumor first described in 2010. It shares histologic, immunohistochemical, and genetic features with secretory carcinoma of the breast. The clinical behavior of MASC ranges from slowly growing tumors that infrequently recur after surgical resection to aggressive tumors that cause widespread metastasis and death. Many cases of MASC were discovered in archived cases previously classified as acinic cell carcinoma, mucoepidermoid carcinoma, and adenocarcinoma not otherwise specified.

Conclusion

MASC is a newly recognized variant of salivary gland malignancy. Further research is needed to better delineate its overall prevalence and to define an appropriate treatment algorithm for this new clinical entity.

Level of Evidence

NA. Laryngoscope, 124:188–195, 2014

Ancillary